Literatur
-
1
Hentig N von.
„Messung von Plasmakonzen-trationen antiretroviraler Arzneimittel in der HIV-Therapie”.
Dtsch Med Wochenschr.
2008;
133
191-195
-
2
Fletcher C, Anderson P, Kakuda T. et al .
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.
AIDS.
2002;
16
551-560
-
3
Burger D, Hugen P, Reiss P. et al .
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.
AIDS.
2003;
17
1157-1165
-
4
Marzollini C T, Decosterd L A, Greub G. et al .
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
AIDS.
2001;
15
71-75
-
5
Langmann P, Weissbrich B, Desch S, Väth T, Schirmer D, Zilly M, Klinker H.
Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
Eur J Med Res.
2002;
7
(7)
309-14
-
6
Katsounas A, Frank A, Klinker H, Langmann P.
Efavirenz-therapy in HIV-patients with underlying liver disease: importance of continuous TDM of EFV.
Eur J Med Res.
2007;
12
(8)
331-6
Priv.-Doz. Dr. med. Peter Langmann
Internist, Gastroenterologie, Hepatologie, Infektiologie, Diabetologie
Am Tiefen Weg 2
97753 Karlstadt
eMail: p_langmann@yahoo.de
